Some aspects of maintaining patients with primary immunodeficiencies with antibodies synthesis disfunction. Data on 10% intravenous immunoglobulin G Gamunex treatment



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

On time diagnostics and correct treatment of patients with PID with humoral deficiency provide a good prognosis. Despite of long experience of intravenous immunoglobulins (IVIG) usage for the treatment of these patients no strict recommendations concerning regimes of treatment exist. This article presents clinical experience about the treatment with 10% IVIG Gamunex in PID patients with immunoglobulin deficiency.

Full Text

Restricted Access

About the authors

E A Latysheva

Institute of Immunology

Moscow, Russia

N H Setdikova

Institute of Immunology

Moscow, Russia

T V Latysheva

Institute of Immunology

Email: tvlat@mail.ru
Moscow, Russia

References

  1. Joshi A.Y., Sauver J.L., Boyce T.G. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin. Proc. 2009, v. 84 (1), p. 16-22.
  2. Eades-Perner A.M., Gathmann B., Knerr V., Guzman D.,Veit D., Kindle G., Grimbacher B. for the ESID Registry Working Party. The European internet-based patient and research database for primary immunodeficiencies: results 2004—06. Clin. Exp. Immunol. 2007, v. 147, p. 306-312.
  3. Stiehm E.R., Ochs H.D., Winkelstein J.A. Immunoglobulin disorders in infants and children. 5th Philadelphia, PA: Elsevier/Saunders. 2004.
  4. Morio T. Common variable immunodeficiency: an update on etiology, pathophysiology, and classification. Nihon Rinsho Meneki Gakkai Kaishi. 2012, v. 35 (1), p. 14-22.
  5. Wang N., Shen N., Vyse T.J. et al. Selective IgA deficiency in autoimmune diseases. Mol Med. 2011, v. 17 (11-12), p. 1383-1396.
  6. Ramalho V.D., Oliveira Júnior E.B., Tani S.M. et al. Mutations of Bruton’s tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia Braz. J. Med. Biol. Res. 2010, Sep., v. 43 (9), p. 910-913.
  7. Winkelstein J.A., Conley M.E., James C. et al. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore). 2008, v. 87 (5), p. 253-258.
  8. Ballow M., Notarangelo L., Grimbacher B., Cunningham-Rundles C. et al. Immunodeficiencies. Clin. Exp. Immunol. 2009, Dec., v. 158 (1), p. 14-22.
  9. Baris S., Ercan H., Cagan H.H. et al. Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency. J. Investig Allergol. Clin. Immunol. 2011, v. 21 (7), p. 514-521.
  10. Lougaris V., Gallizzi R., Vitali M. et al. A novel compound heterozygous TACI mutation in an autosomal recessive Common Variable Immunodeficiency (CVID) family. Hum Immunol. 2012 May 21 http://www.ncbi.nlm.nih.gov/pubmed.
  11. Иммунодефициты у детей. И.В. Сидоренко, И.В. Кондратенко. Кафедра клинической иммунологии и аллергологии ММА им. И. М. Сеченова http://wwwfondpodsolnuh. ru/disease/article.xl?id=711.
  12. Kelsoe G., Cain D. A new guise for hyper-IgM syndrome. Blood. 2010, Dec., 23, v. 116 (26), p. 5785-5786.
  13. Fernandez-Cruz E., Kaveri S.V., Peter H.H. et al. 6th International Immunoglobulin Symposium: poster presentations. Clin. Exp. Immunol. 2009, v. 158 (Suppl. 1), p. 60-67.
  14. Durandy A., Kaveri S.V., Kuijpers T.W. et al. Intravenous immunoglobulins — understanding properties and mechanisms. Clin. Exp. Immunol. 2009, v. 158 (Suppl. 1), p. 2-13.
  15. Bayry J., Lacroix-Desmazes S., Donkova-Petrini V. et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA. 2004, v. 101, p. 14210-14215.
  16. Kaveri S.V., Maddur M.S., Hegde P., Lacroix-Desmazes S., Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin. Exp. Immunol. 2011, Jun, v. 164, Suppl. 2, p. 2-5.
  17. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J. Clin. Immunol. 2008, v. 28 (Suppl. 10), р. 42-45.
  18. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D. et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood. 2004, v. 104, p. 2441-2443.
  19. Cunningham-Rundles C., Radigan L. Deficient IL-12 and dendritic cell function in common variable immune deficiency. Clin Immunol. 2005, v. 115 (2), p. 147-153.
  20. Mackay I.R., Leskovsek N.V., Rose N.R. The odd couple: a fresh look at autoimmunity and immunodeficiency. J. Autoimmun. 2010, v. 35, p. 199-205.
  21. Lucas M., Lee M., Lortan J. et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol. 2010, v. 125, p. 1354-1360.
  22. Jordan S. Orange, William F. Grossman, Roberta J. Navickis, Mahlom M. Wilkes. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin. Immunol. 2010, Oct., v. 137 (1), p. 21-30.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2012



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies